Prothena Corporation plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTA research report →
About the company
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
- CEO
- Gene G. Kinney
- IPO
- 2012
- Employees
- 67
- HQ
- Dublin, DU, IE
Price Chart
- Market Cap
- $507.30M
- P/E
- -3.45
- P/S
- 8.76
- P/B
- 1.66
- EV/EBITDA
- -2.48
- Div Yield
- 0.00%
- Gross Margin
- 46.85%
- Op Margin
- -217.94%
- Net Margin
- -260.92%
- ROE
- -49.88%
- ROIC
- -39.43%
- Revenue
- $9.68M · -92.83%
- Net Income
- $-244,092,000 · -99.57%
- EPS
- $-4.53 · -99.56%
- Op Income
- $-184,560,000
- FCF YoY
- -8.89%
- 52W High
- $11.80
- 52W Low
- $6.16
- 50D MA
- $9.70
- 200D MA
- $9.69
- Beta
- -0.31
- Avg Volume
- 526.92K
Get TickerSpark's AI analysis on PRTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | SCULLY WILLIAM P | buy | 20,000 |
| Jun 15, 26 | SCULLY WILLIAM P | other | 325,000 |
| Jun 11, 26 | SCULLY WILLIAM P | buy | 125,000 |
| Jun 8, 26 | Isaacs Michael John | other | 0 |
| Jun 8, 26 | Isaacs Michael John | other | 17,500 |
| Jun 8, 26 | Isaacs Michael John | other | 10,000 |
| Jun 8, 26 | Isaacs Michael John | other | 8,250 |
| Jun 8, 26 | Isaacs Michael John | other | 8,800 |
| Jun 8, 26 | Isaacs Michael John | other | 12,000 |
| Jun 8, 26 | Isaacs Michael John | other | 8,612 |
Our PRTA coverage
Recent articles, reports, and earnings notes.
No research on PRTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRTA report →Similar companies
Peers in the same neighborhood.